Poor ovarian response to gonadotrophin stimulation is associated with FSH receptor polymorphism

Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype.

Because the ovarian response to FSH stimulation in assisted reproduction is variable, ranging from hyporesponse to hyperresponse, with the possible complication of ovarian hyperstimulation, it would be of great benefit to predict the response of the patients to FSH. To date, no clear-cut predictors of ovarian responsiveness to FSH have been identified. In this study, we investigated the role of...

Variant-beta luteinizing hormone is not associated with poor ovarian response to controlled ovarian hyperstimulation

BACKGROUND The most common genetic variant of luteinizing hormone (LH), variant-betaLH, has a different bioactivity than the wildtype. Carrying the variant allele was associated with an increased consumption of exogenous gonadotropin to achieve optimal ovarian response for in vitro fertilization procedures (IVF). The aim of this study was to examine if variant-betaLH was also more common in pat...

Leukocytosis in response to exogenous gonadotrophin stimulation.

Leukocytosis may develop in women undergoing ovulation induction. The production of blood leukocytes and their numbers in circulation are regulated by complex interactions involving endogenous haematopoietic cytokines, such as granulocyte-colony stimulating factor (G-CSF), monocyte-colony stimulating factor (M-CSF), and interleukins. The purpose of this prospective study was to explore the pres...

Is Lh Needed for Routine Ovarian Stimulation Regimens Using Fsh?

Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer.

AIM We aimed to investigate the clinical significance of the activation of Yes-Associated Protein 1 (YAP1), a key downstream effector of Hippo tumor-suppressor pathway, in ovarian cancer. MATERIALS AND METHODS A gene expression signature reflecting activation of YAP1 was developed from gene expression data of 267 samples from patients with ovarian cancer. A refined ovarian cancer YAP1 signatu...